Abstract:Introduction: Targeted biologic immunomodulatory therapies have had a major impact in rheumatoid arthritis (RA) treatment, including tumor necrosis factor (TNF)-α inhibition, B-cell depletion, interference in T-cell costimulation and interleukin (IL)-1 and IL-6 inhibition. Along with the recognition of the importance of early, aggressive disease-modifying antirheumatic drugs (DMARDs) grounded in the use of methotrexate, the introduction of biologic DMARDs (bDMARDs) has provided significantly improved outcomes in patients with RA with a goal of true remission, or at least a state of very low disease activity, now possible in many. There are a number of methods to inhibit cytokines, cellular receptors and pathways of signal transduction that have been used thus far and are in development. In some cases, the method of target inhibition and differences in molecular construct has impacted efficacy and/or safety; whereas, in other cases, similar safety and/or efficacy signals across compounds have demonstrated class- or target-related effects. As the development of targeted therapies moves forward, it is increasingly important to understand the role of the target both in RA disease pathogenesis and normal host defense and the mechanisms of target inhibition. Areas covered: This review covers the targets of therapy for biologic agents in rheumatic diseases, their molecular constructs and implications on efficacy and safety, with focus on approved treatments for RA. Expert opinion: Advances in molecular biology have provided a number of different ways to impact pathobiologically relevant pathways and targets in terms of the molecular construct of individual compounds. The use of these agents have provided important mechanistic insights into disease pathogenesis, and in some cases are associated with differences in efficacy and safety among agents even with the same downstream target. As bDMARDs identify promising mechanisms, oral agents that target or specifically regulate downstream pathways are made possible.

Pharmacogenomics of biological treatment in rheumatoid arthritis.

Laser light triggered-activated carbon nanosystem for cancer therapy.

Trends of Treatment Development in Rheumatoid Arthritis: Promise, Progress, and Challenges

An AI Approach to Identifying Novel Therapeutics for Rheumatoid Arthritis

Title Current Status of the Search for Biomarkers for Optimal Therapeutic Drug Selection for Patients with Rheumatoid Arthritis

The Role of Resveratrol on Rheumatoid Arthritis: from Bench to Bedside

Genetic Biomarkers as Predictors of Response to Tocilizumab in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

Genetic markers as therapeutic target in rheumatoid arthritis: A game changer in clinical therapy?

Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment

Identifying therapeutic targets for rheumatoid arthritis by genomics-driven integrative approaches

Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis

Molecular and Cellular Heterogeneity in Rheumatoid Arthritis: Mechanisms and Clinical Implications.

Rheumatoid arthritis: advances in treatment strategies

It's not a looming crisis--the crisis is here, now! Re: Manpower in the Canadian neurosurgical workforce: is a crisis looming?

Deciphering the molecular landscape of rheumatoid arthritis offers new insights into the stratified treatment for the condition

Assessing the potential of epigenetic targets as biomarkers in the diagnosis and treatment of rheumatoid arthritis

From molecular subgroups to molecular targeted therapy in rheumatoid arthritis: A bioinformatics approach

Pharmacogenomics on the Treatment Response in Patients with Psoriasis: An Updated Review

Overview of mechanisms and novel therapies on rheumatoid arthritis from a cellular perspective

Efficacy and safety implications of molecular constructs of biological agents for rheumatoid arthritis

Understanding Refractory Rheumatoid Arthritis: Implications for a Therapeutic Approach